Dual agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
=== Plastics and building materials === In one large-scale application, melamine is combined with formaldehyde and other agents to produce melamine resins. Such resins are characteristically durable thermosetting plastic used in high-pressure decorative laminates such as Wilsonart, melamine dinnerware, laminate flooring, and dry erase boards. Melamine cookware is not microwave-safe, and can be identified from the fact it is "slightly heavier and noticeably thicker than its plastic counterparts." Melamine foam is used as insulation, soundproofing material and in polymeric cleaning products, such as Magic Eraser. Melamine is one of the major components in Pigment Yellow 150, a colorant in inks and plastics. Melamine also is used in the fabrication of melamine polysulfonate, used as a superplasticizer for making high-resistance concrete. Sulfonated melamine formaldehyde (SMF) is a polymer used as a cement admixture to reduce the water content in concrete while increasing the fluidity and the workability of the mix during handling and pouring. It results in concrete with a lower porosity and a higher mechanical strength, exhibiting an improved resistance to aggressive environments and a longer lifetime.
== Pharmacology == The OATPs play a role in the transport of some classes of drugs across the cell membrane, particularly in the liver and kidney. In the liver, OATPs are expressed on the basolateral membrane of hepatocytes, transporting compounds into the hepatocyte for biotransformation. A number of drug-drug interactions have been associated with the OATPs, affecting the pharmacokinetics and pharmacodynamics of drugs. This is most commonly where one drug inhibits the transport of another drug into the hepatocyte, so that it is retained longer in the body (i.e. increased plasma half-life). The OATPs most associated with these interactions are OATP1B1, OATP1B3 and OATP2B1, which are all present on the hepatocyte basolateral (sinusoidal) membrane. OATP1B1 and OATP1B3 are known to play an important role in hepatic drug disposition. These OATPs contribute towards first step of hepatic accumulation and can influence the disposition of drug via hepatic route. The most clinically relevant interactions have been associated with the lipid lowering drugs statins, which led to the removal of cerivastatin from the market in 2002. Single nucleotide polymorphisms (SNPs) are also associated with the OATPs; particularly OATP1B1. Many modulators of OATP function have been identified based on in vitro research in OATP-transfected cell lines. Both OATP activation and inhibition has been observed and an in silico model for structure-based identification of OATP modulation was developed.
At the time of their hatching, chicks range in development from helpless to independent, depending on their species. Helpless chicks are termed altricial, and tend to be born small, blind, immobile and naked; chicks that are mobile and feathered upon hatching are termed precocial. Altricial chicks need help thermoregulating and must be brooded for longer than precocial chicks. The young of many bird species do not precisely fit into either the precocial or altricial category, having some aspects of each and thus fall somewhere on an "altricial-precocial spectrum". Chicks at neither extreme but favouring one or the other may be termed semi-precocial or semi-altricial.
=== China === In 2024, China’s supreme court and chief prosecutor jointly issued the Interpretation of Several Issues Concerning the Application of Law in Handling Criminal Cases of Money Laundering (2024). In American and British English, this title would translate to Money Laundering Prosecution Guidelines, and they explain how Criminal Law act section 191 applies to money laundering proceeds from specific unlawful activities. The guidelines treat money laundering done for concealment of criminal proceeds as a section 191 criminal offense both when tied to the offender’s own unlawful activity and when tied to unlawful activity committed by others, and directs courts to assess whether a defendant met a knowledge or reason-to-know standard based on totality-of-the-circumstances factors. The guidelines also identify aggravating circumstances where at least 5,000,000 yuan is laundered with specified sentencing enhancements, sets mandatory minimum fine amounts of 10,000 yuan for sentences up to five years imprisonment or jail and 200,000 yuan for sentences of five to ten years, superseding prior guidance from 2009 money laundering adjudicative guidelines. It is regulated by the China Anti-Money Laundering Monitoring and Analysis Center
Sources: en.wikipedia.org
=== Ice test === Applying ice for 2–5 minutes to the muscles reportedly has a sensitivity and specificity of 76.9% and 98.3%, respectively, for the identification of MG. Acetylcholinesterase is thought to be inhibited at the lower temperature, which is the basis for this diagnostic test. This generally is performed on the eyelids when ptosis is present and is deemed positive if a ≥2-mm rise in the eyelid occurs after the ice is removed.
Since its foundation, the Treaties sought to enable people to pursue their life goals in any country through free movement. Reflecting the economic nature of the project, the European Community originally focused upon free movement of workers: as a "factor of production". However, from the 1970s, this focus shifted towards developing a more "social" Europe. Free movement was increasingly based on "citizenship", so that people had rights to empower them to become economically and socially active, rather than economic activity being a precondition for rights. This means the basic "worker" rights in TFEU article 45 function as a specific expression of the general rights of citizens in TFEU articles 18 to 21. According to the Court of Justice, a "worker" is anybody who is economically active, which includes everyone in an employment relationship, "under the direction of another person" for "remuneration". A job, however, need not be paid in money for someone to be protected as a worker. For example, in Steymann v Staatssecretaris van Justitie, a German man claimed the right to residence in the Netherlands, while he volunteered plumbing and household duties in the Bhagwan community, which provided for everyone's material needs irrespective of their contributions. The Court of Justice held that Mr Steymann was entitled to stay, so long as there was at least an "indirect quid pro quo" for the work he did. Having "worker" status means protection against all forms of discrimination by governments, and employers, in access to employment, tax, and social security rights.
=== Environment === Deforestation in the Brazilian Amazon rainforest fell 61% in January 2023 from a year earlier following a series of anti-logging and anti-mining operations launched by government agencies under Lula, according to satellite data. In June 2023, the Environment Ministry announced a plan to curb deforestation in Brazil's Legal Amazon, and immediately embargoed all activities being developed inside conservation parks in the region. Additionally, the government announced the creation of 3 million hectares (7,413,161.44 acres) in protected areas until 2027/ the creation of tracking system using geopositioning for Amazon agricultural products and ecolabels were announced as well. In July 2023, deforestation in the Brazilian Amazon was reported to have fallen 34% over the previous six months while deforestation in the Brazilian Atlantic forest dropped 42% from January to May 2023 comparatively to the same period of time in 2022. In November 2023, Brazil's National Institute for Space Research (INPE) reported that the Amazon deforestation rate fell 22% between August 2022 and July 2023, compared to its previous 2021–2022 report (during Jair Bolsonaro's presidency). Considering only the period of the Lula government, the drop is accentuated to 49.7% compared to the same period of the previous year. Deforestation in protected areas fell the most, being the lowest in 9 years. In total, Imazon highlighted that 2023 had the lowest deforestation rate since 2017.
=== Discontinued === ABT-436 – vasopressin V1b receptor antagonist – alcoholism Adrogolide (ABT-431; DAS-431) – dopamine D1 receptor agonist – cocaine-related disorders ADX-629 – aldehyde inhibitor / reactive aldehyde species (RASP) inhibitor – alcoholism, alcoholic hepatitis ADX-10061 (CEE-310; CEE-03-310; NNC-010687; NNC-687) – dopamine D1 receptor antagonist – smoking withdrawal, substance-related disorders ADX-71441 – GABAB receptor positive allosteric modulator – alcoholism, cocaine-related disorders, substance-related disorders Anatabine (RCP-006) – nicotinic acetylcholine receptor agonist – smoking withdrawal ANS-6637 (GS-6637; GS-6673) – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism, opioid-related disorders, smoking withdrawal, substance-related disorders Arbaclofen placarbil (R-baclofen placarbil; XP-19986) – GABAB receptor agonist – alcoholism ASP-8062 – GABAB receptor modulator – opioid-related disorders Aticaprant (AVTX-501; CERC-501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY-2456302) – κ-opioid receptor antagonist – alcoholism, cocaine-related disorders, smoking withdrawal Azasetron (nazasetron; Serotone; Y-25130) – serotonin 5-HT3 receptor antagonist – cocaine-related disorders AZD-4041 – orexin OX1 receptor antagonist – smoking withdrawal Baclofen/samidorphan (ALKS-29; ALKS-33/baclofen; baclofen/ALKS-33) – combination of baclofen (GABAB receptor agonist) and samidorphan (μ-opioid receptor antagonist) – alcoholism Befloxatone (MD-370503) – monoamine oxidase A (MAO-A) inhibitor – smoking withdrawal BP-897 – dopamine D3 receptor agonist – cocaine-related disorders BR-9003 (BR-9003A) – undefined mechanism of action – smoking withdrawal BTRX-246040 (LY-2940094) – nociceptin receptor agonist – alcoholism Buprenorphine/naloxone (NanoBUP; NTC-0510; NTC-510) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Buprenorphine/samidorphan (ALKS 33-BUP; ALKS 33/buprenorphine; ALKS-5461; BUP-ALKS 33; buprenorphine/ALKS-33; buprenorphine/RDC 0313; RDC 0313/buprenorphine; samidorphan/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and samidorphan (μ-opioid receptor antagonist) – cocaine-related disorders Cannabidiol (CBD; synthetic cannabidiol; RAD-011) – cannabinoid/various actions – substance-related disorders CVL-936 – dopamine D2 and D3 receptor antagonist – substance-related disorders CX-1739 – AMPA receptor positive allosteric modulator (ampakine) – substance-related disorders Deudimethyltryptamine (HLP004; HLP-004; CYB004; CYB-004; DMT-d10; deuterated dimethyltryptamine; dDMT) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – substance-related disorders Deupsilocin (HLP003; HLP-003; CYB003; CYB-003; psilocin-d10; deuterated psilocin) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism Dianicline (SSR-591813) – nicotinic acetylcholine receptor agonist – smoking withdrawal Drinabant (AVE-1625; INDV-5004; OPNT-004) – cannabinoid CB1 receptor antagonist – substance-related disorders Ecopipam (EBS-101; PSYRX-101; SCH-39166) – dopamine D1 receptor antagonist – cocaine-related disorders Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist – smoking withdrawal Elinzanetant (BAY-3427080; GSK-1144814A; GSK-1144814; Lynkuet; NT-814) – neurokinin NK1 and NK3 receptor antagonist – opioid-related disorders Femoxetine (femoxitine; FG-4963; Malexil; NNC-204963) – selective serotonin reuptake inhibitor (SSRI) – alcoholism Gabapentin enacarbil (ASP8825; Gabapentin-XP; GSK-1838262; Horizant; Regnite; Solzira; XP13512) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel blocker) – alcoholism Gepirone (Ariza; BMY-13805; Exxua; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor agonist – cocaine-related disorders Istradefylline (KW-6002; Nourianz; Nouriast) – adenosine A2 receptor antagonist ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, μ-opioid receptor partial agonist – substance-related disorders JNJ-39393406 – α7 subunit-containing nicotinic acetylcholine receptor positive allosteric modulator – smoking withdrawal JZP-150 – fatty acid amide hydrolase (FAAH) inhibitor – alcoholism Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – cocaine-related disorders Lorcaserin (APD-356; Belviq; E2023; Venespri) – serotonin 5-HT2C receptor agonist – smoking withdrawal Manifaxine (BW-1555U88; GW-320659) – norepinephrine–dopamine reuptake inhibitor (NDRI) – smoking withdrawal Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – smoking withdrawal Nalmefene (CPH-101; JF-1; Lu AA36143; Nalmetrene; NIH-10365; ORF-11676; Selincro; Soberal) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – smoking withdrawal Nepicastat oral (APL-1401; SYN-117) – dopamine β-hydroxylase (DBH) inhibitor – cocaine-related disorders Neramexane (KRP-209; MRZ-2/579) – NMDA receptor antagonist, nicotinic acetylcholine receptor antagonist – alcoholism NIC-002 (NIC002; CYT002-NicQβ; Nicotine-Qβ) – immunostimulant (nicotine vaccine) – smoking withdrawal NicVAX – immunostimulant (nicotine vaccine) – smoking withdrawal Nornicotine – nicotinic acetylcholine receptor agonist – smoking withdrawal NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – alcoholism NYX-783 – ionotropic glutamate NMDA receptor modulator – alcoholism, opioid-related disorders OREX-1019 – μ-opioid receptor agonist, δ-opioid receptor antagonist, κ-opioid receptor antagonist, nociceptin receptor agonist – cocaine-related disorders OREX-1038 – μ-opioid receptor agonist – cocaine-related disorders, opioid-related disorders Oxytocin intranasal (Syntocinon Nasal Spray; TUR-001) – oxytocin receptor agonist – alcoholism Quetiapine (FK-949; FK949E; ICI-204636; Seroquel) – atypical antipsychotic (non-selective monoamine receptor modulator) – alcoholism Rimonabant (Acomplia; SR-141716; SR-141716A; Zimulti) – cannabinoid CB1 receptor antagonist – smoking withdrawal Risperidone (JNJ-410397-AAA; R-64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot) – atypical antipsychotic (non-selective monoamine receptor modulator) – substance-related disorders RTI-113 – dopamine reuptake inhibitor (DRI) (cocaine analogue) – cocaine-related disorders Samidorphan (ALKS-33; RDC-0313; RDC-0313-00) – μ-opioid receptor antagonist – alcoholism, substance-related disorders Sembragiline (EVT-302; RG-1577; RO-4602522) – monoamine oxidase B (MAO-B) inhibitor – smoking withdrawal Serlopitant (JTS-661; MK-0594; VPD-737) – neurokinin NK1 receptor antagonist – alcoholism Surinabant (SR-147778; SR147778) – cannabinoid CB1 receptor antagonist – alcoholism, smoking withdrawal TA-NIC – immunostimulant (nicotine vaccine) – smoking withdrawal Tradipitant (LY-686017; Nereus; VLY-686) – neurokinin NK1 receptor antagonist – alcoholism Verucerfont (GSK-561679; NBI-77860) – corticotropin-releasing factor 1 (CRF1) receptor antagonist Vigabatrin (γ-vinyl-GABA; gamma-vinyl-GABA; GVG; M071754; MDL-71754; RMI-71754; Sabril; Sabrilex) – GABA transaminase (GABA-T) inhibitor – cocaine-related disorders, substance-related disorders
== Research == Muscimol has been clinically studied for a number of potential medical uses. It was assessed in small clinical studies in the treatment of Huntington's disease, tardive dyskinesia, and schizophrenia in the 1970s but was not found to be useful for these indications. Another study evaluated muscimol in schizophrenics with tardive dyskinesia in 1992. Studies also assessed the biochemical effects of muscimol in humans in the late 1970s and early 1980s. According to Povl Krogsgaard-Larsen, muscimol was too toxic and non-selective and as such was not developed for use as a pharmaceutical drug. Instead, the synthetic analogue gaboxadol (THIP), which was more selective and much less toxic, was developed. In 2019, a phase 1 clinical trial of muscimol for drug-resistant epilepsy was published. It has also been formally investigated for potential treatment of Alzheimer's disease and Parkinson's disease. A 2023 systematic review and meta-analysis of 22 preclinical studies found that muscimol reduces neuropathic pain in animals, with effects beginning within 15 minutes and lasting up to 3 hours. Muscimol has never been approved as a pharmaceutical drug for any use anywhere in the world.
Sources: en.wikipedia.org
=== 20 March === The European Union announced that it will be sending a million rounds of shells to Ukraine over the next 12 months. The United States approved a $350 million military aid package for Ukraine. The package includes ammunition for HIMARS rocket launchers, ammunition for Bradley Fighting Vehicles, HARM missiles, anti-tank weapons, riverine boats, and other equipment.
== Properties and ingredients == In a study funded by Aquaphor's parent company, it was found that their "Healing Ointment" product was associated with (but did not cause) decreased redness around the wound but did not perform better than other products clinically. Aquaphor is not comedogenic and does not contain any fragrances, preservatives, or dyes. Unlike Vaseline (100% petrolatum), which is occlusive, Aquaphor (41% petrolatum) claims to form a semi-occlusive barrier on the skin. This theoretically enables the transmission of water and oxygen, which is important for wound healing and the formation of a protective moist healing environment. However, no studies have been conducted using this brand to test these healing claims.
== Biomarkers of disease == It is important to acknowledge the biomarkers of third-hand smoke because they theoretically indicate the severity and presence of disease. In a recent study involving mice, THS biomarkers were discovered after four weeks of initial exposure at equivalent levels to those found in the homes of people who smoke. Researchers used a system that mimicked exposure to humans and sought out biomarkers found in serum, liver, and brain tissues in the mice. The mice were then exposed to THS at varying months and as early as one month, they began to show signs of increased circulating inflammatory cytokines, tumor necrosis factor, granulocyte macrophage colony stimulating factor, and an increase in the stress hormone epinephrine. Damage from THS exposure continued after two, four, and six months. Such damages included oxidative stress and molecular damage. In a small controlled study of healthy nonsmoking adults, acute dermal exposure to third-hand smoke increased urinary biomarkers of oxidative damage to DNA, lipids and proteins and altered the plasma proteome in a pattern similar to that observed in cigarette smokers, including activation of pathways associated with inflammatory skin disease. Some of the mice also became hyperglycemic and hyperinsulinimic, which could mean that insulin resistance could be a consequence of long-term exposure. This study implies that increased exposure time to THS can have dramatic effects.
This is based on the absence of Neanderthal mtDNA, as well as the relatively low level of Neanderthal admixture in the modern human X chromosome. According to Svante Pääbo, it is not clear that modern humans were socially dominant over Neanderthals, which may explain why the interbreeding occurred primarily between Neanderthal males and modern human females. A 2026 study confirmed the evidence of sex bias, reporting that sexual selection (i.e., a preference for male Neanderthals and modern human females) was the primary driver of the asymmetric mating patterns, rather than sex biases in demography or migration. Neanderthals in the Siberian Altai Mountains interbred with the local Denisovan population, and it may have been a common occurrence here. About 17% of the genome of one Altai Denisovan specimen derived from Neanderthals. Even before genetic evidence had confirmed this admixture, hybridisation between Neanderthals and early modern humans had been proposed early on, such as by English anthropologist Thomas Huxley in 1890, Danish ethnographer Hans Peder Steensby in 1907, and Coon in 1962. In the early 2000s, supposed hybrid specimens were discovered: Lagar Velho 1 and Muierii 1. These proposals were based on shared anatomy, but modern geneticists have cautioned that some shared anatomy might have been acquired by adaptation to a similar environment, rather than admixture alone.
=== Pregnancy, lactation, and early childhood === The U.S. Recommended Dietary Allowance (RDA) for pregnancy is 2.6 micrograms per day (μg/d), for lactation 2.8 μg/d. Determination of these values was based on an RDA of 2.4 μg/d for non-pregnant women, plus what will be transferred to the fetus during pregnancy and what will be delivered in breast milk. However, looking at the same scientific evidence, the European Food Safety Authority (EFSA) sets adequate intake (AI) at 4.5 μg/d for pregnancy and 5.0 μg/d for lactation. Low maternal vitamin B12, defined as serum concentration less than 148 pmol/L, increases the risk of miscarriage, preterm birth and newborn low birth weight. During pregnancy the placenta concentrates B12, so that newborn infants have a higher serum concentration than their mothers. As it is recently absorbed vitamin content that more effectively reaches the placenta, the vitamin consumed by the mother-to-be is more important than that contained in her liver tissue. Women who consume little animal-sourced food, or who are vegetarian or vegan, are at higher risk of becoming vitamin depleted during pregnancy than those who consume more animal products. This depletion can lead to anemia, and also an increased risk that their breastfed infants become vitamin deficient. Vitamin B12 is not one of the supplements recommended by the World Health Organization for healthy women who are pregnant, however, vitamin B12 is often suggested during pregnancy in a multivitamin along with folic acid especially for pregnant mothers who follow a vegetarian or vegan diet.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.